|
FOR IMMEDIATE RELEASE
Pharmaceutical companies are pushing many more candidate drugs into early stage trials, but will that be enough to cure the product drought? Proof-of-concept may be the answer.
Malorye A. Branca, Editor-in-Chief, reports on critical new trend
in the premier issue of Pharma DD
NEWTON, MA – May 24, 2006 – Like salmon racing upstream to spawn, drug candidates face many obstacles, and a huge number drop out before reaching the market. In its premier issue, Cambridge Healthtech Institute’s Pharma DD magazine (Pharmaceutical Discovery & Development) takes an in-depth look at the critical issue of how to get more good drugs through the pipeline and onto the market. The premier feature, entitled “Proof of Concept – Pharma’s New Watchword” describes how better tools and approaches may finally bridge discovery and clinical trials. The article includes interviews from leading pharma companies including Pfizer, Wyeth, and Novartis on the technologies and strategies that may allow them to predict a drug failure earlier in the development cycle, and ensure greater success among those that go on to clinical trials.
“Drug failure is the biggest problem for pharmaceutical companies today – it has become an industry-wide dilemma. Even the FDA has become involved in finding ways to improve the process,” says Malorye A Branca, who has covered the pharmaceutical industry for 15 years. “More and better “proof of concept” studies are how most companies are trying to fix that.” They are also doing different kinds of experiments, trying to nail down drug mechanisms before they even go into early human testing. There is now great emphasis on tools that can help bridge preclinical and clinical trial findings, providing greater certainty that drugs work in humans the same way they have acted in animal models.
The issue, being distributed this week at CHI’s World Pharmaceutical Congress in Philadelphia, PA, is also available on line at www.pharmaDD.com. In addition to delivering feature content, Pharma DD also includes:
- Money Matters: The dollars and cents of the pharma industry
- Perspectives: Insightful commentary and controversial views on strategy
- Clinical Connection: Trends and new developments in clinical trials
- Hot Targets: An in-depth look at front runners against leading drug targets
- Bench Notes: Technical briefs and analysis of new scientific techniques
- Deal Watch: A focused look at big deals and what’s behind them
About
Pharma DD
Pharma DD, published 6x per year, provides senior
researchers and scientific management with unique
insight into the industry-leading techniques and
approaches driving
new therapeutic discovery and development. As well as
focusing on business issues, regulatory
considerations, clinical trials, and post-approval
safety issues. The publication and accompanying web
site www.pharmaDD.com,
deliver features, news, commentaries, and case studies
to professionals in pharma, biotech, and research
laboratories. Pharma DD is published by Cambridge
Healthtech Institute, based in Newton Upper Falls, MA
About
Cambridge Healthtech Institute
CHI’s renowned conferences are the underpinning for
all our other information resources. Each year, CHI
organizes over 80 conferences held throughout the US.
including The
Molecular Medicine Tri-Conference, Beyond
Genome, PepTalk,
World
Pharmaceutical Congress and the new acquired
Bio-IT World’s Life Sciences Conference & Expo.
The company strives to develop quality programs
that provide valuable new insights and competing
points of view while offering balanced coverage of the
latest developments. Basic research related to
commercial implications is covered, with heavy
emphasis placed on end-user insights into new products
and technology as well as coverage on the strategy
behind the business. Leading researchers and business
experts from top pharmaceutical, biotech and academic
organizations present their most current findings in a
forum that features panel discussions and audience
participation. Over the past 14 years, CHI has
produced more than 400 conferences, attracting more
than 50,000 attendees from around the world.
In
addition to CHI’s vast conference portfolio, their
media properties include PharmaWeek,
available on the web only, Pharma
DD, and Bio-IT
World, Inc.
For more information, contact:
Malorye Allison Branca
Editor-in-Chief
978-264-0758
editor@pharmadd.com
Press Contact :
Lisa Scimemi
Cambridge Healthtech Institute
Ph. (617) 630-1319
lscimemi@healthtech.com
|
